Evan Rachlin is the Co-Founder and Managing Partner of Ascenta Capital, a biotech venture fund. His career combines high-level strategy and investment, with previous roles as a Managing Director at Blackstone Life Sciences, Head of Strategy at Moderna, and Principal at Bain Capital Ventures. He holds both an MD and an AB from Harvard University.
Evan demonstrates a strong commitment to pediatric healthcare through his role on the board of the Boston Childrens Hospital Trust. This philanthropic involvement reflects a dedication to advancing medical care and supporting community health initiatives beyond his direct investment work.
Unique fact: Evan graduated magna cum laude from Harvard with a degree in Biochemistry and Japanese before earning his MD.
Evan Rachlin
Co-Founder and Managing Partner at Ascenta Capital
United States
Overview
Topics They Care About
Biotech Investing
Co-founded Ascenta Capital, which raised a $325M fund to invest in development-stage biotechnology companies, focusing on firms with multi-medicine platforms.
Corporate Strategy
As former Head of Strategy at Moderna, he led the development of the company's long-range plan and helped formulate its portfolio and financing strategy.
Healthcare Leadership
Serves on the boards of several portfolio companies, including Iambic Therapeutics and Alpha-9 Oncology, guiding their clinical, regulatory, and capital strategy.
Media Appearances
Ascenta Capital Announces Final Close of $325 Million Inaugural Fund. Featured in Business Wire
Work History
Co-Founder and Managing Partner at Ascenta Capital
Managing Director at Blackstone Life Sciences
Head of Strategy at Moderna
Principal at Bain Capital Ventures
Engagement Manager at McKinsey & Company
Education
MD/MBA from Harvard University
AB from Harvard University
More Information
Social Presence :
Prographics :
Exp : N/A
Location : United States
Job Level : Leadership
Designation : Co-Founder and Managing Partner at Ascenta Capital
